Anti-CD19 monoclonal antibody and uses thereof

The R19mab monoclonal antibody addresses the limitations of existing CAR-positive cell detection methods by offering high sensitivity and specificity, enabling accurate identification and monitoring of CAR-T cells, crucial for quality control and clinical treatment.

JP7588413B2Active Publication Date: 2024-11-22BIOSWAN LAB INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2021536403
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-12-20
Filing Date
2019-12-17
Publication Date
2024-11-22
Estimated Expiration
2039-12-17

AI Technical Summary

Technical Problem

Current methods for detecting CAR-positive cells, such as CAR-T cells, suffer from low sensitivity and accuracy, particularly in distinguishing between CAR-positive T cells and B cells, and cannot effectively monitor treatment efficacy and recurrence risks.

Method used

Development of a highly sensitive and specific monoclonal anti-CD19 antibody, R19mab, with optimized CDR sequences, allowing for high-affinity binding to the CD19 CAR extracellular antigen-binding region, and a detection kit for accurate identification of CAR-positive cells using flow cytometry.

Benefits of technology

The R19mab antibody achieves a detection sensitivity of 1 CD19 CAR-positive cell per 10,000 cells, providing precise differentiation between positive and negative cells, enhancing quality control and clinical treatment monitoring of CAR-T drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007588413000002
    Figure 0007588413000002
  • Figure 0007588413000003
    Figure 0007588413000003
  • Figure 0007588413000004
    Figure 0007588413000004
Patent Text Reader

Abstract

The present invention provides anti-CD19 monoclonal antibodies and uses thereof. These monoclonal antibodies against CD19 have high specificity and strong affinity. Furthermore, the present invention also provides detection reagents and detection methods for CAR-T cells that have high sensitivity, accuracy, and specificity, and that can directly target the extracellular antigen-binding domain of CAR-T cells.
Need to check novelty before this filing date? Find Prior Art

Description

Detailed Description of the Invention

[0001] Technical Field The present invention relates to the fields of biotechnology and medicine, and specifically to monoclonal antibodies of anti-CD19 antibodies and uses thereof.

[0002] Background technology With the development of tumor immunotherapy, immunotherapy using chimeric antigen receptor (CAR)-T cells, which combines the advantages of antibodies and immune cells, has attracted much attention. CAR is mainly composed of an extracellular antigen-binding domain and an intracellular signaling domain via a hinge domain and a transmembrane domain. The extracellular antigen-binding domain has the function of specifically recognizing and binding to the surface antigen of the target cell, and is composed of a single chain variable domain (single chain variable fragment, scFv) of a monoclonal antibody, and the heavy chain variable domain (V H ) and the light chain variable region (V L ). The intracellular signaling domain mainly consists of a costimulatory signal and the CD3ζ chain of the T cell receptor (TCR). When a T (CAR-T) cell expressing a CAR binds to an antigen on a target cell via the scFv, the intracellular signaling domain transmits a signal into the T cell, activating the T cell and secreting perforin, granzymes, cytokines, etc., to exert a killing effect. Currently, two CAR-T cell drugs approved for marketing by the FDA are Kymriah from Novartis and Yescarta from Gilead. Both drugs are directed against tumors of CD19-positive B cells and use a similar antigen-binding domain, i.e., scFv derived from the mouse monoclonal antibody FMC63.

[0003] To construct CAR-T cells, the CAR gene needs to be transfected into the genome of T cells by a virus or non-viral system. Without the normal expression of the gene and the formation of a transmembrane CAR structure in the cell membrane, CAR-T cells will not have the activity to recognize and kill target cells. Therefore, accurate detection of CAR-expressing positive T cells is a key step in the quality control of CAR-T drugs, and is also an important part of controlling the therapeutic dosage of patients in clinical practice, monitoring their progress, and auxiliary diagnosis. There are two common detection methods: detecting CAR gene-positive T cells and detecting CAR protein-positive T cells.

[0004] Methods for detecting CAR gene-positive T cells: Quantitative polymerase chain reaction (qPCR) is the main method for detecting CAR gene-positive T cells. qPCR can detect the CAR gene integrated into the genome of cells and the copy number of the CAR gene. However, this method cannot accurately reflect the positive T cells expressing CAR, because some T cells integrated with the CAR gene do not express CAR normally (Jennifer N. Brudno et al., Journal of Clinical Oncology, 2016), and the false positive rate of these T cells reduces the accuracy of the use of the qPCR method. More seriously, the qPCR method cannot distinguish between CAR-positive T cells and CAR-positive B cells, making it difficult to detect the treatment and risk of relapse caused by CAR-positive B cells (Marco Ruella et al., Nature Medicine, 2018). In addition, the qPCR method cannot meet the demand for simultaneously detecting multiple surface markers of T cells (CD3, CD4, CD8, etc.), which further limits the application of the qPCR method.

[0005] Methods for detecting CAR protein-positive T cells: Existing detection reagents include anti-mouse IgG (Fab')2 (Jackson ImmunoResearch), Protein L (Zhili Zheng et al., Journal of Translational Medicine, 2012), CD19 / Fc (Satiro N De Oliveira et al., Journal of Translational Medicine, 2013), GFP-CD19 (Patent Application No. 201610354642.0), mouse monoclonal antibody 136.20.1 (PCT / US2014 / 039365; Bipulendu Jena et al., PLoS One, 2013). Among them, anti-mouse IgG (Fab')2 and Protein L have low sensitivity for detecting CD19 CAR and cannot distinguish different CARs (e.g., CD22 CAR, BCMA CAR, etc.) constructed with different scFvs derived from mice. Both CD19 / Fc and GFP-CD19 rely on the binding of CD19 protein to FMC63 scFv in CD19 CAR, and the affinity of the scFv to CD19 is significantly lower than that of the complete antibody FMC63 to CD19 (IAN C. Nicholson et al., Molecular Immunology, 1997), so CD19 / Fc and GFP-CD19 have low sensitivity for detecting CD19 CAR. Mouse monoclonal antibody 136.20.1 detects CD19 CAR, and depends on the binding of the antibody to FMC63 scFv in CD19 CAR, with a detection sensitivity close to 1:1000, that is, one positive cell is detected in 1000 cells, and when applied to the detection of CD19 CAR positive cells in the body, there is still a defect that the sensitivity is not high. All the above reagents have a small range of application due to their respective difficult to overcome reasons.

[0006] Therefore, there is a strong need in this field to develop highly sensitive and accurate detection reagents and methods for detecting CAR-positive cells to meet the needs of quality control, clinical treatment and auxiliary diagnosis of CAR-T drugs.

[0007] Summary of the Invention An object of the present invention is to provide a highly sensitive and accurate detection reagent for CAR-positive cells and use thereof.

[0008] In a first aspect of the present invention, a heavy chain variable region of an antibody is provided, comprising the following three complementarity determining regions CDRs: CDR1 as shown in SEQ ID NO:3: GIDFRNYG (SEQ ID NO:3); CDR2 as shown in SEQ ID NO: 4: FSSSGST (SEQ ID NO: 4); and CDR3 shown in SEQ ID NO: 5: ARHGPTNGWKL (SEQ ID NO: 5) The present invention provides a heavy chain variable region comprising:

[0009] In another preferred embodiment, the heavy chain variable region has the amino acid sequence set forth in SEQ ID NO:9. QSLEESGGRLVTPGTPLTLTCTVSGIDFRNYGVSWVRQAPGKGLEWIGIFSSSGSTYYATWAKGRFTISKASSTTVDLKMTSLTTEDTATYFCARHPGPTNGWKLWGPGTLVTVSS (SEQ ID NO: 9) In a second aspect of the invention there is provided a heavy chain of an antibody, the heavy chain having a heavy chain variable region and a heavy chain constant region according to the first aspect of the invention.

[0010] In another preferred embodiment, the heavy chain constant region is of rabbit, mouse or human origin. In a third aspect of the invention, a light chain variable region of an antibody is provided, comprising a complementarity determining region CDR selected from the group consisting of: CDR1′ as shown in SEQ ID NO:6: QSVSGY (SEQ ID NO:6); CDR2': RAS (SEQ ID NO: 7) as shown in SEQ ID NO: 7; and CDR3' shown in SEQ ID NO: 8: QSNYNSGSSSSAAA (SEQ ID NO: 8) The present invention provides a light chain variable region having the following structure:

[0011] In another preferred embodiment, the light chain variable region has the amino acid sequence set forth in SEQ ID NO:10. DVVMTQTPASVEAPVGGTVTIKCQASQSVSGYCSWYQQKPGQPPKLLIYRASTLESGVPSRFSGSGSGTDFTLTISDLECADAATYYCQSNYNSGSSSSAAAFGGGTEVVVK (SEQ ID NO: 10) In a fourth aspect of the invention, there is provided a light chain of an antibody, the light chain having a light chain variable region and a light chain constant region according to the third aspect of the invention.

[0012] In another preferred embodiment, the constant region of the light chain is of rabbit, mouse or human origin. In a fifth aspect of the present invention, (1) a heavy chain variable region according to the first aspect of the invention, and / or (2) A light chain variable region according to the third aspect of the present invention. The present invention provides an antibody having the formula:

[0013] In another preferred embodiment, the antibody has a heavy chain according to the second aspect of the invention and / or a light chain according to the fourth aspect of the invention. In another preferred embodiment, the antibody is a specific anti-CD19 antibody.

[0014] In another preferred embodiment, the antibody comprises a single chain antibody (scFv), a Fab or (Fab')2 fragment, a double chain antibody, a monoclonal antibody, a chimeric antibody (e.g., a human-rabbit chimeric antibody, a rabbit-mouse chimeric antibody), a rabbit-derived antibody, a mouse-derived antibody, or a humanized antibody.

[0015] In another preferred embodiment, the dissociation equilibrium constant of the antibody with the scFv of the CD19 antibody is K D ≦1 nM, preferably K D ≦100 pM, most preferably K D ≦50 pM. In another preferred embodiment, the CD19 antibody is the mouse monoclonal antibody FMC63.

[0016] In another preferred embodiment, the scFv of the CD19 antibody is present in the cell membrane of a CAR-T cell in the form of a CAR. In another preferred embodiment, the trade names of the CAR-T cells are Kymriah and Yescarta.

[0017] In a sixth aspect of the present invention, (i) a heavy chain variable region according to the first aspect of the invention, a heavy chain according to the second aspect of the invention, a light chain variable region according to the third aspect of the invention, a light chain according to the fourth aspect of the invention, or an antibody according to the fifth aspect of the invention; (ii) an optional tag sequence to aid in expression and / or purification; The present invention provides a recombinant protein having the following structure:

[0018] In another preferred embodiment, the tag sequence comprises a secretory peptide tag. In another preferred embodiment, the tag sequence comprises a 6His tag and / or an Fc tag. In another preferred embodiment, said recombinant protein is a specific anti-CD19 antibody.

[0019] In a seventh aspect of the invention, a polypeptide selected from the group consisting of: (1) a heavy chain variable region according to the first aspect of the invention, a heavy chain according to the second aspect of the invention, a light chain variable region according to the third aspect of the invention, a light chain according to the fourth aspect of the invention, or an antibody according to the fifth aspect of the invention; or (2) A recombinant protein according to the sixth aspect of the present invention. A polynucleotide encoding the compound is provided.

[0020] In an eighth aspect of the invention there is provided a vector comprising a polynucleotide according to the seventh aspect of the invention. In another preferred embodiment, the vector comprises a bacterial plasmid, a phage, a yeast plasmid, a plant cell virus, a mammalian cell virus (eg, adenovirus, retrovirus, lentivirus, etc.), a transposon or other vector.

[0021] In a ninth aspect of the present invention there is provided a genetically engineered host cell which comprises a vector according to the eighth aspect of the invention or has incorporated into its genome a polynucleotide according to the seventh aspect of the invention.

[0022] In a tenth aspect of the present invention, (a) a heavy chain variable region according to the first aspect of the invention, a heavy chain according to the second aspect of the invention, a light chain variable region according to the third aspect of the invention, a light chain according to the fourth aspect of the invention, or an antibody according to the fifth aspect of the invention; (b) a conjugate moiety selected from the group consisting of a detectable marker, a drug, a toxin, a cytokine, a radionuclide, an enzyme, a magnetic bead, agarose, and the like; The present invention provides an immunoconjugate comprising:

[0023] In another preferred embodiment, the conjugated moiety is selected from a fluorescent or luminescent marker, a radioactive marker, an MRI (magnetic resonance imaging) or CT (computed tomography) contrast agent, or an enzyme generating a detectable product, a radionuclide, a biological toxin, a gold nanoparticle / nanorod, any type of nanoparticle, or any type of granule of any other size (e.g. magnetic beads, agarose granules), etc.

[0024] In an eleventh aspect of the present invention, there is provided a detection reagent for detecting CD19 CAR-positive cells, comprising: There is provided a detection reagent comprising a first detection reagent which is a first antibody according to the fifth aspect of the invention.

[0025] In another preferred embodiment, the detection reagent further comprises a second detection reagent that specifically binds to the first antibody or to a marker conjugated to the first antibody. In another preferred embodiment, the first antibody is a monoclonal antibody conjugated with a fluorescent or luminescent marker.

[0026] And, the detection reagent has a detection sensitivity of ≧1 CD19 CAR-positive cell / 1000 cells. In another preferred embodiment, the first antibody is an unmodified monoclonal antibody.

[0027] In another preferred embodiment, the second detection reagent is a second antibody specifically directed against the first antibody. In another preferred embodiment, the first antibody is a biotinylated monoclonal antibody and the second detection reagent is streptavidin carrying a detectable marker.

[0028] In another preferred embodiment, the detection reagent has a detection sensitivity of ≧1 CD19 CAR-positive cell / 1000 cells, preferably ≧5 CD19 CAR-positive cells / 1000 cells, more preferably ≧1 CD19 CAR-positive cell / 10,000 cells, and even more preferably ≧2 CD19 CAR-positive cells / 100,000 cells.

[0029] In another preferred embodiment, the monoclonal antibody is a rabbit-derived monoclonal antibody. In another preferred embodiment, the first and second antibodies are from different mammalian species.

[0030] In another preferred embodiment, the first antibody is of rabbit origin and the second antibody is of donkey or goat origin. In another preferred embodiment, the CAR positive cells include CAR immune cells and CAR non-immune cells.

[0031] In another preferred embodiment, the CAR-positive cells are selected from the group consisting of T cells, NK cells, CIK cells, NKT cells, or combinations thereof. In another preferred embodiment, the CAR-positive cells include HEK-293T cells, Jurkat cells, or a combination thereof.

[0032] In another preferred embodiment, the monoclonal antibody further comprises one or more of the following characteristics: (i) EC of binding to CD19 CAR scFv recombinant protein 50 is 0.3 to 3 nM, preferably 0.3 to 1 nM; (ii) the effective concentration for binding to the CD19 CAR scFv recombinant protein is 0.02 to 0.2 μg / mL, preferably 0.02 to 0.1 μg / mL; (iii) a dissociation equilibrium constant for binding to the CD19 CAR scFv recombinant protein of 10 -10 ~10 -12 It's M.

[0033] In another preferred embodiment, the monoclonal antibody specifically recognizes and binds to a CD19 CAR constructed based on the scFv of the anti-CD19 monoclonal antibody FMC63. In another preferred embodiment, the extracellular antigen-binding region of the CD19 CAR has the amino acid sequence shown in SEQ ID NO:1. DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGGGGSGGGGSGGGGSEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSS (SEQ ID NO: 1) In another preferred embodiment, the CD19 CAR scFv recombinant protein has the structure of CD19 CAR scFv-His tag.

[0034] In another preferred embodiment, the CD19 CAR scFv recombinant protein has the amino acid sequence shown in SEQ ID NO:2. DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGGGGSGGGGSGGGGSEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSSHHHHHH (SEQ ID NO: 2)

[0035] In another preferred embodiment, the monoclonal antibody is produced by the following method: (a) providing a CD19 CAR scFv recombinant protein; and (b) obtaining antisera against the CD19 CAR scFv recombinant protein by immunizing rabbits with the recombinant protein; and (c) obtaining a single clone of rabbit B cells against said CD19 CAR scFv recombinant protein by performing monoclonal culture on peripheral blood B cells of the immunized rabbit and screening for a single clone of positive B cells; and (d) sequencing the single clone of the positive rabbit B cells to obtain the gene sequence of the light / heavy chain of the monoclonal antibody; and (e) constructing an expression plasmid with the gene sequence of the light / heavy chain of the monoclonal antibody and transfecting it into a eukaryotic host cell, thereby obtaining a transfected eukaryotic host cell; and (f) expressing the monoclonal antibody by culturing the transfected eukaryotic host cells under conditions suitable for expression; and (g) isolating and / or purifying the monoclonal antibody from the culture system.

[0036] In another preferred embodiment, the expression comprises secreted expression (ie, secreted into the cell culture medium). In another preferred embodiment, the eukaryotic host cell is selected from the group consisting of HEK-293T cells, CHO cells, COS-1 cells, and COS-7 cells.

[0037] In another preferred embodiment, the CD19 CAR scFv recombinant protein has the amino acid sequence set forth in SEQ ID NO: 1 or 2. In another preferred embodiment, said CD19 CAR scFv recombinant protein comprises a recombinant protein by eukaryotic or prokaryotic expression.

[0038] In another preferred embodiment, the CD19 CAR scFv recombinant protein is a recombinant protein expressed by E. coli. In another preferred embodiment, the CD19 CAR scFv recombinant protein is renatured.

[0039] In another preferred embodiment, the CD19 CAR scFv recombinant protein is by eukaryotic expression. In another preferred embodiment, the CD19 CAR scFv recombinant protein is produced by the following method: (a) providing an expression plasmid containing an expression cassette for the CD19 CAR scFv recombinant protein; (b) transfecting a eukaryotic host cell with said expression plasmid, thereby obtaining a transfected eukaryotic host cell; (c) expressing the recombinant protein by culturing the transfected eukaryotic host cells under conditions suitable for expression; and (d) isolating and / or purifying the recombinant protein from the culture system.

[0040] In another preferred embodiment, the expression comprises secreted expression (ie, secreted into the cell culture medium). In another preferred embodiment, the eukaryotic host cell is selected from the group consisting of HEK-293T cells, CHO cells, COS-1 cells, and COS-7 cells.

[0041] In a twelfth aspect of the invention, there is provided a method of producing a first antibody, which is a monoclonal antibody that specifically binds to the extracellular antigen-binding region of a CD19 CAR, comprising: A method is provided comprising the steps of: (a) providing a CD19 CAR scFv recombinant protein; and (b) obtaining antisera against the CD19 CAR scFv recombinant protein by immunizing rabbits with the recombinant protein; and (c) obtaining a single clone of rabbit B cells against said CD19 CAR scFv recombinant protein by performing monoclonal culture on peripheral blood B cells of the immunized rabbit and screening for a single clone of positive B cells; and (d) sequencing the single clone of the positive rabbit B cells to obtain the gene sequence of the light / heavy chain of the monoclonal antibody; and (e) constructing an expression plasmid with the gene sequence of the light / heavy chain of the monoclonal antibody and transfecting it into a eukaryotic host cell, thereby obtaining a transfected eukaryotic host cell; and (f) expressing the monoclonal antibody by culturing the transfected eukaryotic host cells under conditions suitable for expression; and (g) isolating and / or purifying the monoclonal antibody from the culture system.

[0042] In another preferred embodiment, the expression comprises secreted expression (ie, secreted into the cell culture medium). In another preferred embodiment, the eukaryotic host cell is selected from the group consisting of HEK-293T cells, CHO cells, COS-1 cells, and COS-7 cells.

[0043] In another preferred embodiment, the CD19 CAR scFv recombinant protein has the amino acid sequence shown in SEQ ID NO: 1 or 2. In another preferred embodiment, the method further optionally comprises the steps of: (h) optionally performing performance measurements on the isolated and / or purified monoclonal antibodies.

[0044] In another preferred embodiment, the performance measurement comprises detection of one or more selected from the group consisting of: (i) Detection of specificity; (ii) titer detection; (iii) detection sensitivity; (vi) detection of blockage of neutralization; (v) Detection of binding kinetics.

[0045] In another preferred embodiment, the first antibody is an antibody according to the fifth aspect of the invention. In a thirteenth aspect of the present invention, there is provided a CD19 CAR detection kit, comprising: (t1) a first container containing a monoclonal antibody according to the fifth aspect of the invention, which specifically binds to the extracellular antigen-binding region of CD19 CAR; and optionally, (t0) instructions A detection kit is provided, comprising:

[0046] In another preferred embodiment, the monoclonal antibody has a detectable marker. In another preferred embodiment, the detectable marker comprises a fluorescent or luminescent marker.

[0047] In another preferred embodiment, the monoclonal antibody is a monoclonal antibody having a fluorescent marker. In another preferred embodiment, the detection kit further comprises (t2) a second container containing a second antibody specifically directed against the monoclonal antibody.

[0048] In another preferred embodiment, the first container and the second container may be integrated or separate. In another preferred embodiment, the second antibody is an anti-rabbit IgG antibody.

[0049] In another preferred embodiment, the second antibody is selected from the group consisting of donkey anti-rabbit IgG antibody and goat anti-rabbit IgG antibody. In another preferred embodiment, the second antibody carries a detectable marker.

[0050] In another preferred embodiment, the detectable marker comprises a fluorescent or luminescent marker. In another preferred embodiment, the second antibody is a secondary antibody carrying a fluorescent marker.

[0051] In another preferred embodiment, the detection kit further comprises one or more additional detection reagents selected from the following group: (t3) a third container, and a blocking agent in the third container; and (t4) a fourth container, and a positive control (e.g., a CD19 CAR scFv recombinant protein) located within the fourth container; and (t5) a fifth container, and a negative control reagent located within the fifth container.

[0052] In another preferred embodiment, the additional detection reagent is located in the same or a different container. In another preferred embodiment, the instructions describe a method for detecting CD19 CAR-positive cells.

[0053] In a fourteenth aspect of the present invention, there is provided the use of a detection reagent according to the eleventh aspect of the present invention in the manufacture of a reagent or kit for detecting CD19 CAR-positive cells. In another preferred embodiment, the CAR positive cells include CAR immune cells and CAR non-immune cells.

[0054] In another preferred embodiment, the CAR-positive cells are selected from the group consisting of T cells, NK cells, CIK cells, NKT cells, or combinations thereof. In another preferred embodiment, the CAR-positive cells include HEK-293T cells, Jurkat cells, or a combination thereof.

[0055] In a fifteenth aspect of the invention, there is provided a method for detecting CD19 CAR-positive cells, comprising: (I) providing a detection reagent according to the eleventh aspect of the present invention; (II) detecting a test cell population with the detection reagent to obtain a qualitative or quantitative detection result of CD19 CAR-positive cells; The present invention provides a method comprising:

[0056] In another preferred embodiment, the method comprises: (1) 1×10 5 ~1×10 6 and washing the test cells 1 to 3 times with a buffer solution containing a blocking agent (e.g., PBS containing 1% blocking agent); (2) resuspending the cells in a buffer solution containing 50 to 200 μL of a blocking agent and a monoclonal antibody having a detectable marker (e.g., PBS containing 1% blocking agent and 1 to 100 ng of the monoclonal antibody) and allowing the cells to stand at 2 to 15° C. (preferably 4±2° C.) for a certain period of time T1 (e.g., 10 to 60 minutes, preferably about 15 to 45 minutes); (3) washing the cells 1 to 3 times with a buffer solution (e.g., PBS); (4) Resuspending the cells in a certain amount (e.g., 100 to 500 μL) of a buffer solution (e.g., PBS) and detecting the cells in a flow cytometer. Includes.

[0057] In another preferred embodiment, the detectable marker comprises a fluorescent or luminescent marker. In another preferred embodiment, the monoclonal antibody is a monoclonal antibody having a fluorescent marker.

[0058] In another preferred embodiment, the method comprises: (1) 1×10 5 ~1×10 6 and washing the test cells 1 to 3 times with a buffer solution containing a blocking agent (e.g., PBS containing 1% blocking agent); (2) resuspending the cells in a buffer solution containing 50 to 200 μL of a blocking agent and a first antibody (monoclonal antibody) (e.g., PBS containing 1% blocking agent and 1 to 100 ng of the monoclonal antibody, e.g., R19mab), and allowing the cells to stand at 2 to 15° C. (preferably 4±2° C.) for a certain period of time T1 (e.g., 10 to 60 minutes, preferably about 15 to 45 minutes); (3) washing the cells 1 to 3 times with a buffer solution (e.g., PBS); (4) resuspending the cells in 50-200 μL of a buffer solution (PBS containing 100-500 ng of the secondary antibody) having a detectable marker (e.g., a fluorescent group) and incubating the cells at 2-15° C. (preferably 4±2° C.) for a certain period of time T2 (e.g., 10-60 minutes, preferably about 15-30 minutes); (5) washing the cells 1 to 3 times with a buffer solution (e.g., PBS); (6) Resuspending the cells in a certain amount (e.g., 100 to 500 μL) of a buffer solution (e.g., PBS) and detecting the cells in a flow cytometer. Includes.

[0059] In another preferred embodiment, the method is an in vitro detection method. In another preferred embodiment, the method is a non-diagnostic, non-therapeutic method. In another preferred embodiment, the method is a method for quality control.

[0060] Of course, it is understood that within the scope of the present invention, the above technical features of the present invention and the technical features specifically described below (for example, in the Examples) can be combined with each other to form new or preferred technical solutions, which will not be described here one by one due to space limitations. [Brief description of the drawings]

[0061] [Figure 1] FIG. 1 shows the titer results of detecting CD19 CAR-positive cells with the rabbit antiserum of the present invention. [Diagram 2] Figure 2 shows the results of detecting CD19 CAR-positive cells in monoclonal culture supernatants of rabbit B cells. [Diagram 3] FIG. 3 shows the results of an ELISA experiment of the binding of the rabbit monoclonal antibody R19mab of the invention to FMC63 scFv and FMC63, where it is compared with the data for the mouse monoclonal antibody 136.20.1. [Figure 4] FIG. 4 shows the results of detecting different target CAR-T (CD19 CAR-T and BCMA CAR-T) cells with the rabbit monoclonal antibody R19mab of the present invention. [Diagram 5] Figure 5 shows the results of blocking the binding of R19mab to CD19 CAR-T by FMC63 scFv. Figure 5A shows the blocking effect of different concentrations of FMC63 scFv, and Figure 5B shows the IC50 measurement results of the blocking effect of FMC63 scFv. [Figure 6] Figure 6 shows the EC50 measurement of R19mab binding to CD19 CAR scFv on the cell surface. [Figure 7] FIG. 7 shows the results of measuring the sensitivity of R19mab binding to CD19 CAR-positive cells, where it is compared with data from mouse monoclonal antibody 136.20.1 and CD19 / Fc. [Figure 8] Figure 8 shows the results of immunofluorescence detection of binding of R19mab to CD19 CAR scFv on the cell surface. [Figure 9]FIG. 9 shows the results of a kinetic analysis of binding of R19mab to FMC63 scFv. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0062] Specific embodiments The present inventors have conducted extensive and in-depth research and conducted a large number of screenings, and unexpectedly obtained an anti-19 monoclonal antibody R19mab. Experimental results show that the monoclonal antibody against the CD19 antibody has high specificity and strong affinity. The present invention also provides a detection reagent with high detection sensitivity, good accuracy and excellent specificity for CAR-T cells, and a detection method based on the detection reagent of the present invention, which not only directly targets the extracellular antigen-binding region of CAR-T cells, but also has a detection sensitivity far higher than that of various existing detection reagents. The detection reagent of the present invention also has a very high degree of discrimination between positive and negative CAR-T cells, and the detection result is more accurate. Based on this, the present invention has been completed.

[0063] term As used herein, the term "antibody" or "immunoglobulin" refers to a heterotetrameric glycoprotein of approximately 150,000 daltons with similar structural characteristics, consisting of two identical light chains (L) and two identical heavy chains (H). Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide bonds between the heavy chains depends on the immunoglobulin isotype. Each heavy and light chain also has regularly spaced intrachain disulfide bonds. Each heavy chain has a variable region (VH) at one end followed by multiple constant regions. Each light chain has a variable region (VL) at one end followed by a constant region at the other end. The constant region of the light chain faces the first constant region of the heavy chain, and the variable region of the light chain faces the variable region of the heavy chain. Special amino acid residues form an interface between the light and heavy chain variable regions.

[0064] As used herein, the term "variable" refers to the fact that certain portions of the variable regions of antibodies differ in sequence, which constitutes the binding and specificity of each particular antibody to its particular antigen. However, variability is not uniformly distributed throughout the variable regions of antibodies. It is concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions in the variable regions of the light and heavy chains. In the variable regions, the relatively conserved portions are called framework regions (FRs). Natural heavy and light chain variable regions each contain four FR regions that are essentially in a β-sheet structure, connected by three CDRs that form connecting loops, and sometimes in a partial β-sheet structure. The CDRs in each chain are in close proximity through the FR regions and together with the CDRs of the other chain form the antigen-binding site of the antibody (see Kabat et al., NIH Publ. No. 91-3242, Vol. I, pp. 647-669 (1991)). The constant region is not directly involved in binding of an antibody to an antigen, but exhibits different effector functions, such as participating in antibody-dependent cellular toxicity of the antibody.

[0065] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a class of nearly homogeneous colonies, i.e., each individual antibody contained within the colony is alike, except for a few possible naturally occurring mutations. Monoclonal antibodies are highly specific and directed against a single antigenic site, and unlike conventional polyclonal antibody preparations (which are usually different antibodies directed against different antigenic determinants), each monoclonal antibody is directed against a single antigenic determinant on the antigen. In addition to their specificity, an advantage of monoclonal antibodies is that they may be synthesized by recombinant expression in eukaryotic cells, free from the risk of contamination by other immunoglobulins. The modifier "monoclonal" refers to the character of the antibody, and being obtained from a nearly homogeneous antibody colony, should not be construed as requiring the production of the antibody by any special method.

[0066] The present invention includes not only complete monoclonal antibodies, but also immunologically active antibody fragments, such as single chain antibodies, Fab or (Fab')2 fragments, antibody heavy chains, and antibody light chains. As used herein, the terms "heavy chain variable region" and "V H " can be used interchangeably.

[0067] As used herein, the terms "variable region" and "complementarity determining region (CDR)" can be used interchangeably. In one preferred embodiment of the invention, the heavy chain variable region of the antibody comprises the following three complementarity determining regions: CDR1, amino acid sequence: GIDFRNYG (SEQ ID NO:3); CDR2, amino acid sequence: FSSSGST (SEQ ID NO:4); CDR3, amino acid sequence: ARHGPTNGWKL (SEQ ID NO:5).

[0068] In another preferred embodiment, the amino acid sequence of the heavy chain variable region is QSLEESGGRLVTPGTPLTLTCTVSGIDFRNYGVSWVRQAPGKGLEWIGIFSSSGSTYYATWAKGRFTISKASSTTVDLKMTSLTTEDTATYFCARHPGPTNGWKLWGPGTLVTVSS (sequence number 9).

[0069] In one preferred embodiment of the invention, the heavy chain of the antibody comprises the above-mentioned heavy chain variable region and heavy chain constant region, and the heavy chain constant region may be of rabbit, murine or human origin.

[0070] As used herein, the terms "light chain variable region" and "V L " can be used interchangeably. In one preferred embodiment of the invention, the light chain variable region of the antibody according to the invention comprises a complementarity determining region CDR selected from the group consisting of: CDR1', amino acid sequence: QSVSGY (SEQ ID NO:6); CDR2', amino acid sequence: RAS (SEQ ID NO:7); CDR3', amino acid sequence: QSNYNSGSSSSAAA (SEQ ID NO:8).

[0071] In another preferred embodiment, the amino acid sequence of the light chain variable region is DVVMTQTPASVEAPVGGTVTIKCQASQSVSGYCSWYQQKPGQPPKLLIYRASTLESGVPSRFSGSGSGTDFTLTISDLECADAATYYCQSNYNSGSSSSAAAFGGGTEVVVK (sequence number 10).

[0072] The invention also provides other proteins or fusion expression products of the antibodies of the invention. In particular, any protein or protein conjugate and fusion expression product (i.e., immunoconjugates and fusion expression products) having heavy and light chains containing variable regions are included in the invention, provided that their variable regions are similar to or have at least 90%, preferably at least 95%, homology with the variable regions of the heavy and light chains of the antibodies of the invention.

[0073] As used herein, the term "CAR" refers to a chimeric antigen receptor, which includes an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain includes a target-specific binding element (also called an antigen-binding domain). The intracellular domain includes a costimulatory signaling region and a zeta chain portion. The costimulatory signaling region includes a portion of the intracellular domain of a costimulatory molecule. A costimulatory molecule is a cell surface molecule that is required for an effective response of lymphocytes to antigens.

[0074] kit The present invention also provides a detection kit for detecting CD19 CAR, comprising: (t1) a first container; and a monoclonal antibody having a detectable marker in the first container, the monoclonal antibody specifically binding to an extracellular antigen-binding region of a CD19 CAR. (t0) Instructions and A detection kit (direct labeling method) comprising the steps of:

[0075] In another preferred embodiment, the detectable marker comprises a fluorescent or luminescent marker. In another preferred embodiment, the monoclonal antibody is a monoclonal antibody having a fluorescent marker.

[0076] In another preferred embodiment, the detection kit (secondary antibody method) comprises: (t1) a first container; and a monoclonal antibody in the first container, the first antibody specifically binding to an extracellular antigen-binding region of the CD19 CAR. (t2) a second container, and a second antibody in the second container specifically against the monoclonal antibody; (t0) Instructions and Includes.

[0077] In another preferred embodiment, the second antibody is an anti-rabbit IgG antibody. In another preferred embodiment, the second antibody is selected from the group consisting of donkey anti-rabbit IgG antibody and goat anti-rabbit IgG antibody.

[0078] In another preferred embodiment, the second antibody carries a detectable marker. In another preferred embodiment, the detectable marker comprises a fluorescent or luminescent marker.

[0079] In another preferred embodiment, the second antibody is a secondary antibody carrying a fluorescent marker. In another preferred embodiment, the detection kit further comprises one or more additional detection reagents selected from the following group: (t3) a third container, and a blocking agent in the third container; and (t4) a fourth container, and a positive control (e.g., a CD19 CAR scFv recombinant protein) located within the fourth container; and (t5) a fifth container, and a negative control reagent located within the fifth container.

[0080] In another preferred embodiment, the additional detection reagent is located in the same or a different container. In another preferred embodiment, the instructions describe a method for detecting CD19 CAR-positive cells.

[0081] Detection Method The present invention also provides a method for detecting CAR-positive cells based on the monoclonal antibody of the present invention. The monoclonal antibody of the present invention has high affinity and high specificity for the antigen-binding region of the matching or corresponding CAR, and is therefore useful for efficient, sensitive and accurate detection of CAR-positive cells.

[0082] Representative examples of CAR-positive cells detectable by the method of the present invention include, but are not limited to, various cells such as T cells, NK cells, NKT cells, CIK cells, etc. For example, the rabbit monoclonal antibody (R19 mab) against the FMC63 scFv of the present invention is useful for detecting the corresponding CD19 CAR-positive cells (including T cells, NK cells, NKT cells, or CIK cells).

[0083] The detection method of the present invention is useful for scientific research, research and development of cellular medicines, quality control of cellular medicines, monitoring of clinical treatment of cellular medicines, auxiliary diagnosis of clinical patients, etc. The main advantages of the present invention are:

[0084] (a) Dissociation equilibrium constant K of the rabbit monoclonal antibody R19mab of the present invention with FMC63 scFv D The value reaches 43 pM, and the detection sensitivity of R19mab measured by flow cytometry reaches 1:10,000, so the detection kit for CAR-positive cells developed based on the monoclonal antibody of the present invention has high detection sensitivity and good specificity.

[0085] (b) The detection reagents and methods of the present invention have a very high degree of discrimination between CAR-positive cells and CAR-negative cells, resulting in more accurate detection results. (c) The rabbit monoclonal antibody of the present invention has high affinity for mouse-derived FMC63 (significantly superior to the affinity of mouse monoclonal antibodies for mouse-derived FMC63).

[0086] (d) The rabbit monoclonal antibody of the present invention can detect CD19 CAR-positive cells more specifically, sensitively and accurately than existing detection reagents such as anti-mouse IgG (Fab')2, protein L, CD19 / Fc, GFP-CD19, and mouse monoclonal antibody 136.20.1, and can meet the needs of quality control of CAR-T drug production, as well as clinical treatment monitoring and auxiliary diagnosis.

[0087] (e) The rabbit monoclonal antibody and kit of the present invention have significantly reduced production costs, which is more advantageous in the application of CAR-T drug quality control as well as clinical treatment monitoring and auxiliary diagnosis.

[0088] The present invention will be further described below with reference to specific examples. It is understood that these examples are only used to illustrate the present invention and do not limit the scope of the present invention. Experimental methods for which no specific conditions are given in the following examples are generally performed according to standard conditions, such as those described in Sambrook et al., "Molecular Cloning: A Laboratory Manual" (New York, Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer's recommended conditions. Unless otherwise stated, percentages and parts are by weight.

[0089] Common Methods 1. T Cell Activation and Infection with CD19 CAR Lentivirus (1) 0.5 × 10 6 of T cells (0.5 × 10 6 / mL) and place in a 24-well plate; (2) Wash the anti-CD3 / CD28-coated magnetic beads with R10 medium three times according to the manufacturer's instructions; (3) Add magnetic beads to T cells at a ratio of 3:1 (magnetic beads:cells) and culture overnight in a 37°C, 5% CO2 incubator; (4) After activating the T cells for 12 to 24 hours, the 24-well plate was centrifuged and 800 μL of the supernatant culture medium was removed; (5) Dissolve the lentivirus particles at room temperature, mix gently to homogenize, and dissolve 0.5 × 10 lentivirus particles in 1 mL of the solution. 6 Add polybrene to the T cells (200 μL) to a final concentration of 8 μg / mL, place in a centrifuge and centrifuge at 2500 rpm for 1.5 hours, then place in a 37°C, 5% CO2 incubator and culture overnight; (6) Centrifuge the 24-well plate after overnight culture to remove most of the supernatant medium containing the lentiviral particles, and add fresh R10 medium to amplify the T cells; (7) Count T cells every 2 days, add 50 IU / mL of IL-2, and culture 0.5–1 × 10 T cells. 6 / mL; (8) 3~5 days later, 2×10 5 The cells are then taken and CD19 CAR-T cells are detected using a flow cytometer.

[0090] 2. Detection of CD19 CAR-T cells by flow cytometry (secondary antibody method) (1) 2×10 5 Take CD19 CAR-T cells, wash them twice with PBS, and resuspend the cells in 100 µL of PBS; (2) Add the appropriate dilution of detection antibody (or other detection reagent) and incubate at 4°C for 45 minutes; (3) Wash twice with PBS; (4) Add fluorescent secondary antibody and leave at 4℃ for 30 minutes away from light; (5) Wash twice with PBS; (6) Resuspend in 200 μL of PBS and load into a flow cytometer for detection.

[0091] 3. Detection of CD19 CAR-T cells by flow cytometry (direct labeling method) (1) 2×10 5 Take CD19 CAR-T cells, wash them twice with PBS, and resuspend the cells in 100 µL of PBS; (2) Add fluorescently labeled detection antibody (or other detection reagent) at the appropriate dilution ratio and incubate at 4°C for 45 minutes; (3) Wash twice with PBS; (4) Resuspend in 200 μL of PBS and load into a flow cytometer for detection.

[0092] Example 1. Method for producing anti-FMC63 scFv rabbit monoclonal antibody (R19mab) (1) Production and purification of recombinant antigens An expression plasmid containing the FMC63 scFv-His tag recombinant antigen sequence (amino acid sequence shown in SEQ ID NO: 2) was constructed. 293T cells were cultured in an adherent culture in a 10 cm culture dish, and the expression plasmid containing the FMC63 scFv-His tag recombinant antigen sequence was transfected into the 293T cells according to the instructions for Lipofectamine. Six days after transfection, the culture medium was harvested, the cells were removed by centrifugation, and the supernatant was obtained. The recombinant antigen in the supernatant was purified according to the instructions for Ni-NTA Superflow from QIAGEN.

[0093] Results: After purification, the antigen concentrations were 0.5-4 mg / mL. (2) Immunization of rabbits with recombinant antigens The purified recombinant protein was used as an antigen to immunize rabbits. In other words, 0.5 mL of Freund's complete adjuvant was thoroughly and homogeneously mixed with 0.5 mL of antigen (200 μg). Each rabbit was immunized at four sites (either the back or the thigh base) with 0.25 mL at each site. The immunization cycle was 20 days, and blood was collected 7 to 10 days after the completion of immunization to detect the titer of the antiserum, and immunization was performed 4 to 5 times in total.

[0094] (3) Measurement of the titer of rabbit antiserum to detect CD19 CAR-positive cells The lentiviral plasmid containing FMC63 scFv CD19 CAR sequence and the lentiviral plasmid containing BCMA CAR sequence were mixed with three packaging plasmids VSVg, gag / pol, and rev, respectively, and transfected into 293T cells with Lipofectamine reagent. 24 and 48 hours after transfection, the cell supernatants were collected, filtered and ultracentrifuged to obtain purified CD19 CAR lentivirus and BCMA CAR lentivirus, respectively, and stored at -80°C. 293T cells were infected with CD19 CAR lentivirus to obtain CD19 CAR-293T cells. Rabbit antiserum was gradient-diluted with chilled FACS buffer. 2×10 5 CD19 CAR-293T cells were suspended in 50 μL of FACS buffer. Then, 50 μL of antiserum dilution solution was added to 50 μL of cell suspension, and the mixture was incubated on ice for 30 minutes. Then, the cells were washed twice with chilled FACS buffer. Goat anti-rabbit IgG(H+L)-Alexa Fluor 647 secondary antibody (Table 1) was added, and the mixture was incubated on ice for 30 minutes, after which the cells were washed twice with chilled FACS buffer. The cells were resuspended in 200 μL of FACS buffer and detected by flow cytometer.

[0095] result: As shown in Figure 1, when the rabbit antiserum was used at a dilution of 1:16000, it could successfully detect CD19 CAR-positive cells, indicating that the titer reached at least ≧1:16000. The recombinant antigen prepared in Example 1(1) can efficiently generate specific anti-FMC63 scFv antibodies in rabbits.

[0096] (4) Screening of single rabbit B cell clones A single clone of rabbit B cells expressing anti-FMC63 scFv antibody was screened by the method of Stefan Seeber et al. (Stefan Seeber et al., PLoS ONE, 2014). That is, peripheral blood producing anti-FMC63 scFv antibody was taken and peripheral blood mononuclear cells were isolated. The single clone of positive B cells was enriched with FMC63 scFv recombinant protein, and the single clone of B cells was further cultured in a 96-well plate. After 7 days, the culture supernatant of B cells was taken and a flow cytometry experiment was performed in the same manner as described in Example 1 (3) to identify a positive clone of rabbit B cells expressing anti-FMC63 scFv antibody. The positive clone was digested and the heavy / light chain genes were obtained by RT-PCR. An expression vector of the heavy / light chain genes was constructed and transfected into 293T cells for expression. After 7 days, the cell culture supernatant was collected and a flow cytometry experiment was performed in the same manner as described in Example 1(3) to identify the anti-FMC63 scFv monoclonal antibody, and the heavy / light chain gene sequences of the obtained antibody were sequenced.

[0097] result: As shown in Figure 2, the culture supernatant of B cells was detected and screened by flow cytometry, and it was confirmed that No. 0231 was a positive clone of rabbit B cells expressing anti-FMC63 scFv antibody. The heavy / light chain gene sequences of the obtained antibody were sequenced, and the antibody was identified as R19mab.

[0098] (5) Purification of rabbit monoclonal antibody R19mab The culture supernatant of 293T cells expressing R19mab was loaded onto a Protein A chromatography column at a flow rate of approximately 1 mL / min, and the resin was washed with 20 mL of equilibration buffer (20 mM Na2HPO4, 0.15 M NaCl, pH 7.0) and the flow rate was maintained at approximately 2 mL / min. The antibody was eluted with 10 mL of elution buffer (0.1 M glycine, pH 3.0) at a flow rate of approximately 1 mL / min, the eluate was collected, and immediately 1 / 10 volume of neutralization buffer (1 M Tris, pH 8.5) was added to adjust the pH to 7.4. After concentrating to 1-1.5 mL in an ultrafiltration tube, the antibody concentration was measured by spectrophotometer.

[0099] Results: After purification, the concentration of R19mab antibody was 0.5-4 mg / mL. Example 2. Structural characterization of R19mab R19mab comprises a heavy chain variable region and a light chain variable region, the complementarity determining region of the heavy chain variable region comprising CDR1, whose amino acid sequence is set forth in SEQ ID NO:3, CDR2, whose amino acid sequence is set forth in SEQ ID NO:4, and CDR3, whose amino acid sequence is set forth in SEQ ID NO:5, and the complementarity determining region of the light chain variable region comprising CDR1', whose amino acid sequence is set forth in SEQ ID NO:6, CDR2', whose amino acid sequence is set forth in SEQ ID NO:7, and CDR3', whose amino acid sequence is set forth in SEQ ID NO:8.

[0100] Example 3. Characterization of the binding properties of R19mab In this example, the binding of R19mab to FMC63 and FMC63 scFv was detected by ELISA. The binding of R19mab to CD19 CAR on the cell surface was detected by flow cytometry and immunofluorescence. The binding kinetics of R19mab to FMC63 scFv was analyzed by Fortebio Octet.

[0101] (1) ELISA analysis The binding specificity of R19mab to FMC63 and FMC63 scFv was detected by ELISA experiments as follows.

[0102] 96-well titration plates were coated with 100 μL (100 ng) of purified FMC63 scFv recombinant protein, FMC63 antibody or mouse IgG in PBS at 1 μg / mL, and incubated overnight at 4°C. Then, they were blocked with 300 μL / well of PBST containing 5% BSA (PBS containing 0.05% Tween20). Different concentrations of R19mab (0.022-5.625 μg / mL) were added to each well and incubated for 1 h at ambient temperature. The plates were washed with PBST and incubated with goat anti-rabbit IgG polyclonal antibody coupled with horseradish peroxidase (HRP) for 30 min at room temperature. After washing, the plates were developed with ABTS substrate and analyzed by spectrophotometer at OD 405.

[0103] result: As shown in Figure 3, the results of the ELISA experiment showed that R19mab bound to FMC63 scFv and FMC63 antibody, but did not bind to mouse IgG, indicating that R19mab specifically recognized FMC63 scFv and FMC63 antibody and did not cross-react with other mouse-derived IgG. EC 50 The EC value for binding of R19mab to FMC63 was 0.307 nM, the effective binding concentration was 0.022 μg / mL, and the saturation binding concentration was 0.352 μg / mL. 50 The binding concentration of mouse monoclonal antibody 136.20.1 expressed by Cooper et al. to FMC63 was 0.253 nM, with an effective binding concentration of 0.002 μg / mL and a saturation binding concentration of 0.25 μg / mL. The binding concentration of mouse monoclonal antibody 136.20.1 to FMC63 was 2 μg / mL and a saturation binding concentration of 4 μg / mL. R19mab has a significant advantage over 136.20.1.

[0104] Therefore, under similar conditions, the effective binding concentration of the antibody of the present invention is as low as 0.002 μg / mL, while the effective binding concentration of the existing antibody is 2 μg / mL, a difference between the two of about 1000 times. In addition, the saturation binding concentration of the antibody of the present invention is 0.25 μg / mL, which is about 125 times the effective binding concentration, while the saturation binding concentration of the existing antibody is only twice the effective binding concentration, so that the detection range of the antibody of the present invention is wide, thereby enabling cost reduction.

[0105] (2) Flow cytometry research (I) Binding of CD19 CAR-T cells T cells were infected with CD19 CAR lentivirus or BCMA CAR lentivirus to obtain the corresponding CAR-T cells. R19mab, Protein L and the same type of control (rabbit IgG) antibody (Table 1) were diluted in 50 μL of chilled FACS buffer. 2 × 10 5 The cells were suspended in 50 μL of FACS buffer. Then, 50 μL of antibody solution was added to 50 μL of cell suspension, and the mixture was incubated on ice for 30 min. Then, the cells were washed twice with chilled FACS buffer. After the corresponding secondary antibody (R19mab, rabbit IgG / goat anti-rabbit IgG (H+L), Alexa Fluor 488; protein L / streptavidin, FITC; Table 1) was added, and the mixture was incubated on ice for 30 min, the cells were washed twice with chilled FACS buffer. The cells were resuspended in 200 μL of FACS buffer and detected by flow cytometer.

[0106] result: As shown in Figure 4A, R19mab recognizes the CD19 CAR structure on the cell surface, but does not recognize the BCMA CAR structure, and the only difference between the two is the scFv portion. Therefore, R19mab specifically recognizes CD19 CAR-positive cells containing the FMC63 scFv sequence. In contrast, Protein L cannot distinguish between CD19 CAR and BCMA CAR, and has no specificity in detection. In addition, R19mab can clearly distinguish between CD19 CAR-positive and negative cell groups, and the signal peaks of the two do not overlap. On the other hand, the detection results of Protein L show partial overlap of negative and negative signals, and it is not possible to clearly distinguish between positive and negative cell groups, resulting in low detection accuracy.

[0107] As shown in Figure 4B, when detecting CD19 CAR-T cells with R19mab, the positive signal (boxed) is completely separated from the negative signal. When detecting CD19 CAR-T cells with the mouse monoclonal antibody 136.20.1 developed by Cooper et al., neither CD4-positive nor CD8-positive CAR-T (boxed) are completely separated from the negative T cells.

[0108] Therefore, in terms of detection specificity and accuracy, the rabbit monoclonal antibody R19mab of the present invention is far better than Protein L and mouse monoclonal antibody 136.20.1. Furthermore, when combined with detection methods specifically directed against CD4 and / or CD8, the methods of the present invention can more effectively distinguish between two subpopulations of CAR-positive CD4-positive T cells and CD8-positive T cells.

[0109] R19mab has high specificity and accuracy, and can clearly distinguish between CD19 CAR-positive and -negative cell groups, allowing for convenient and accurate counting of CD19 CAR-positive cells, which is very important for the quality control of CD19 CAR-T drug production and auxiliary diagnosis of clinical treatment.

[0110] (II) Blockade of R19mab binding to CD19 CAR-T by FMC63 scFv Purified FMC63 scFv recombinant protein was gradient diluted in 1x PBS, and R19mab (final concentration 0.1 μg / mL) was added to the diluent and incubated together on ice for 30 min. 5 CD19 CAR-T cells were suspended in 100 μL of FACS buffer. Then, FMC63 scFv / R19mab mixed solution was added to the cell suspension, and flow cytometry experiments were performed in the same manner as described in Example 3(2)(I) to analyze the blocking effect of FMC63 scFv on the binding of R19mab to CD19 CAR-T.

[0111] result: As shown in Figure 5, FMC63 scFv effectively blocked the binding of R19mab to CD19 CAR-T (Figure 5A) and reduced the IC 50 The antibody titer was 6.37 nM (0.955 μg / mL) (Figure 5B). R19mab was shown to specifically recognize the FMC63 scFv fragment in the CD19 CAR.

[0112] (III) CD19 CAR-293 T cell binding 293T cells were infected with CD19 CAR lentivirus to obtain CD19 CAR-293T cells. R19mab was gradient diluted in chilled FACS buffer. 2 × 10 5 CD19 CAR-293T cells were suspended in 50 μL of FACS buffer, and then 50 μL of R19mab antibody solution was added to 50 μL of cell suspension, and flow cytometry experiments were performed in the same manner as described above to analyze the binding effect of R19mab.

[0113] result: As shown in Figure 6, R19mab effectively binds to CD 19 CAR scFv on the cell surface and inhibits EC 50 was 1.58 nM.

[0114] (IV) Analysis of detection sensitivity of R19mab CD19 CAR-T cells were mixed with different numbers of PBMC cells at CAR-T:PBMC cell ratios ranging from 1:10 to 1:10000. Flow cytometry experiments were performed using the same method as described in Example 1(3) to analyze the sensitivity of R19mab to detect CD19 CAR-positive cells.

[0115] result: As shown in Figure 7, R19mab could detect 2 CD19 CAR positive cells from 100,000 negative cells, with a detection sensitivity of 0.002%. The mouse monoclonal antibody 136.20.1 invented by Cooper et al. had a detection sensitivity of 0.1% (Bipulendu Jena et al., PLoS One, 2013), and CD19 / Fc (numbered AF488-CD19sIg1-4 in the text) had a detection sensitivity of 0.5% (Satiro N De Oliveira et al., Journal of Translational Medicine, 2013). Therefore, in terms of detection sensitivity, R19mab is far better than mouse monoclonal antibody 136.20.1 and CD19 / Fc. R19mab has high sensitivity, which can conveniently and accurately count low abundance CD19 CAR positive cells, which is very important for the detection of CD19 CAR-T cells in the body, monitoring of clinical treatment and auxiliary diagnosis.

[0116] (3) Immunofluorescence detection CD19 CAR-T cells were washed with 1x PBS and then fixed in 4% paraformaldehyde for 20 min at room temperature. After washing the cells with 1x PBS, they were incubated with blocking solution (10% donkey serum in PBS) for 30 min at room temperature. After washing the cells with 1x PBS, they were incubated with R19mab for 1 h, washed with 1x PBS, and then incubated with goat anti-rabbit IgG(H+L)-Cy3 secondary antibody for 30 min. The cells were smeared and then observed and photographed by confocal microscopy.

[0117] result: As shown in Figure 8, R19mab can clearly stain CD19 CAR-positive T cells, and the red signal on the membrane represents the location of CD19 CAR on the cell membrane. CD19 CAR-negative T cells have no red fluorescent signal. Blue fluorescence represents the cell nucleus.

[0118] (4) Analysis of binding kinetics using Fortebio Octet Kinetic analysis of R19mab binding to FMC63 scFv was completed by Fortebio Octet. Briefly, the biosensor was equilibrated offline in PBS buffer for 600 s, followed by online detection for 60 s to establish a baseline. Purified FMC63 scFv recombinant protein was diluted to 50 μg / mL in PBS, then loaded onto the sensor and held for 60 s. In addition, the FMC63 scFv-loaded sensor was exposed to different concentrations of R19mab (15.6 nM to 0.975 nM, 5 concentrations) for 600 s, after which the sensor was transferred to PBS for dissociation for 900 s to measure dissociation rate. Data was analyzed by Data Analysis 6.2 evaluation software, and kinetic analysis was performed with a 1:1 binding model.

[0119] result: As shown in Figure 9, the dissociation equilibrium constant K D The binding affinity reached 43 pM, indicating that R19mab bound to FMC63 scFv with high affinity, which is consistent with the detection results of the sensitivity of R19mab mentioned above.

[0120] Example 4. Flow cytometry detection kit for CD19 CAR positive cells using R19mab (1) A kit containing the following reagents was prepared (direct labeling method): (a) a first container and a fluorescently labeled R19mab in the first container (wherein the fluorescent can be selected from various fluorescent substances such as FITC, PE, Alexa Fluor 647, etc.); (b) a second container and NC (negative control reagent) in said second container.

[0121] The kit is used as follows. (I) 2×10 5 Take the test cells and wash them twice with PBS (containing 1% blocking agent); (II) Resuspend the cells in 100 μL of PBS (containing 1 μL of fluorescently labeled R19mab) and place at 4°C for 45 min; (III) Wash twice with PBS; (IV) Resuspend in 200 μL of PBS and load into a flow cytometer for detection.

[0122] The results of detecting CD19 CAR-T cells using the kit showed that the kit has high sensitivity and good specificity. (2) A kit containing the following reagents was prepared (secondary antibody method): (a) a first container and R19mab in said first container; (b) a second container and a fluorescent secondary antibody in the second container (wherein the fluorescent agent can be selected from various fluorescent agents such as FITC, PE, Alexa Fluor 647, etc.); (c) a third container and a NC (negative control reagent) in said third container; and (d) a fourth container and a blocking agent within the fourth container.

[0123] The kit is used as follows. (I) 2×10 5 Take the test cells and wash them twice with PBS (containing 1% blocking agent); (II) Resuspend the cells in 100 μL of PBS (containing 1% blocking agent and 1 μL R19mab) and place at 4°C for 45 min; (3) Wash twice with PBS; (4) Resuspend the cells in 100 μL of PBS (containing 0.1 μL of fluorescent secondary antibody) and place at 4°C for 30 minutes away from light; (5) Wash twice with PBS; (6) Resuspend in 200 μL of PBS and load into a flow cytometer for detection.

[0124] The results of detecting CD19 CAR-T cells using the kit showed that the kit has high sensitivity and good specificity.

[0125] [Table 1]

[0126] All documents related to the present invention are incorporated herein by reference as if each document were incorporated individually. After reading the above content of the present invention, it will be understood that those skilled in the art can make various changes and modifications to the present invention, and that equivalent forms thereof are within the scope of the claims of the present invention.

Claims

1. (1) a heavy chain variable region comprising the following three complementarity determining regions (CDRs): CDR1 as shown in SEQ ID NO:3, CDR2 as set forth in SEQ ID NO:4, and CDR3 as shown in SEQ ID NO:5, and (2) A light chain variable region containing the following three CDRs: CDR1' as shown in SEQ ID NO:6, CDR2' as set forth in SEQ ID NO:7, and CDR3' shown in SEQ ID NO:8 An antibody having the formula: The antibody specifically binds to an anti-CD19 antibody, wherein the anti-CD19 antibody is mouse monoclonal antibody FMC63 or FMC63 scFv.

2. The antibody of claim 1, characterized in that the heavy chain variable region has the amino acid sequence shown in SEQ ID NO:

9.

3. The antibody described in claim 1, characterized in that the light chain variable region has the amino acid sequence shown in SEQ ID NO:

10.

4. The antibody that specifically binds to an anti-CD19 antibody is a single chain antibody (scFv), Fab or (Fab') 2 4. The antibody of any one of claims 1 to 3, comprising a fragment, a double-chain antibody, or a monoclonal antibody.

5. An antibody described in any one of claims 1 to 3, characterized in that the antibody that specifically binds to an anti-CD19 antibody comprises a rabbit-derived antibody.

6. 1. An immune complex comprising: (a) an antibody according to any one of claims 1 to 5; (b) a conjugate moiety selected from the group consisting of a detectable marker, a drug, a toxin, a cytokine, a radionuclide, an enzyme, a magnetic bead, or agarose; An immune complex containing

7. A detection reagent for detecting CD19 CAR-positive cells, comprising: A detection reagent comprising a first detection reagent which is an antibody according to any one of claims 1 to 5.

8. A CD19 CAR detection kit, comprising: (t1) a first container containing an antibody according to any one of claims 1 to 5, the antibody specifically binding to the extracellular antigen-binding region of CD19 CAR; and optionally, (t0) instructions A detection kit comprising:

9. 8. Use of the detection reagent of claim 7 in the manufacture of a reagent or kit for detecting CD19 CAR-positive cells.

10. 1. An in vitro method for detecting CD19 CAR positive cells, comprising: (I) providing a detection reagent according to claim 7; (II) detecting a test cell population with the detection reagent to obtain a qualitative or quantitative detection result of CD19 CAR-positive cells; The method includes:

Citation Information

Patent Citations

  • Method for detecting CAR cell, and application of method

    CN108490174A

  • Method for detecting CD19 CAR (chimeric antigen receptor) positive cells and application of the method

    CN108508200A

  • Anti-idiotypic antibodies and related methods

    WO2018023100A2

  • Antigen binding molecules and methods of use thereof

    WO2018064205A1